Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:21 August 2023

MAGMA: This phase III trial is trying to understand whether to give glioblastoma patients chemotherapy as soon as possible following surgery and prior to chemoradiotherapy; and how many cycles of standard adjuvant chemotherapy to give patients after chemoradiotherapyA multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This trial is trying to understand: (1) whether to give metronomic temozolomide as soon as possible following surgery and prior to chemoradiotherapy; and (2) whether to give 6 cycles of standard schedule adjuvant temozolomide chemotherapy (5/28 day cycles) after chemoradiotherapy, or continue temozolomide until progression. Patients will be randomised to a specific arm of treatment, unless they decide not to participate in the randomisation process and are instead assigned to an arm at their clinician's discretion.

Age

People 18+

Phase

III

Trial Acronym

MAGMA

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

ACTRN12620000048987
COGNO 19/03, CTC 0252

Commercial Sponsor

National Health & Medical Research Council (NHMRC)

Scientific Title

A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma

Share with email